TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07864623: A Postmarketing Study of LEQEMBI in Participants With Alzheimer's Disease

Sponsor: Eisai Inc. · Phase: PHASE2 · Area: CNS_NEUROLOGY · Target Enrollment: 270 pts

Competing Trials Overlap

3 Active Trials

Excess Burn Exposure

$12,416,000

Rescue Site Savings

+$8,186,800

Unlock Full NCT07864623 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07864623 Rescue Dossier →